To the Editor:
I read with interest the article regarding treatment of atrial fibrillation (AF) with antiarrhythmic drugs (AADs) or radiofrequency ablation (RFA) by Calkins et al. 1 They describe meta-analysis of data from 1990 to 2007 in comparing different treatment strategies for maintenance of sinus rhythm. Their conclusion is that RFA is more effective and is associated with a lower rate of complications than AADs. Their report has several flaws over and above standard concerns about meta-analysis; the most important problem being the authors combine assessment of patients with paroxysmal AF and persistent AF, 2 different disorders involving very different patient populations and extremely different therapies. If one were to consider the report as written, combining all the patients with AF, then there are several biases toward the RFA group. First, the patient populations are significantly different, which is not surprising because the RFA group studied mostly patients with paroxysmal AF (70%), as compared with the AAD group (56%). As expected, the RFA group was younger (55.5 years versus 61.6 years) and had a lower incidence of ischemic heart disease (10% versus 18%) and structural heart disease (30.6% versus 49.5%).
Second, the AADs studied included many agents recognized as ineffective or dangerous in the patient population. 2 The authors should have considered therapy that was safe and effective for all inclusive patients, such as amiodarone and dronedarone, and not only those approved by the FDA for any type of AF. Third, the considered RFA studies are from an on-average era that is significantly later than the AADs studies. More than 68% of the RFA studies were published since 2004, whereas since then, only 12% of the AADs studies were published. Over the course of that time, therapies have changed. Non-AAD therapy is not adjusted for. Therapy for coronary heart disease, congestive heart failure, and cardiovascular risk factors, such as hypertension and lipid therapy, have been shown to play an important role in management of AF. 3, 4 Background management of AF itself has changed over this time period. Before 2000, digoxin was the most commonly preferred agent for rate control, and anticoagulation was less often used. 5 More recently, digoxin is used sparingly and rate control is more often achieved with ␤-blockers, drugs with many more beneficial advantages. These types of therapy differences are not only important for general management but also for determining responses to the primary question. ␤-Blockers are more effective than digoxin in preventing AF and in controlling the rate should AF recur. This difference would reduce the frequency of patients reporting symptomatic recurrences. Fourth, most of the AAD studies were multicenter projects with central monitoring systems and intense follow-up scrutiny (68%). In comparison, many of the RFA reports were mostly single-site and self-reporting, lacking outside scrutiny regarding occurrences and complications (81%).
Fifth, the authors failed to mention the major difference of these types of therapies. Utilization of AADs for rhythm control is time-consuming and often involves background rate control with anticoagulation during the process of choosing the right AAD. This includes determining the best-tolerated agents and correct dose of AADs. During this time, recurrent AF does not constitute failure, especially because patients should have appropriate rate control and anticoagulation. Catheter ablation is quite another approach, with an entirely different process and set of risks and benefits. Most importantly, the procedure is very operator-dependent, which is very different from AAD therapy, in which the operator is a less important variable. In many RFA studies, the patients have a 3-month blanking period after the procedure when recurrent AF is not considered a failure. This flexible time is not commonly considered for AAD studies. Finally, many of the patients in the RFA studies were also receiving AADs.
I would like to include some recommendations to Calkins et al in their suggested prospective study in comparing these types of therapies. In considering efficacy, an implanted loop recorder would be helpful to minimize reliance on patient or investigator reporting. In addition to efficacy, side effects and quality of life should be measured. This would include complications from RFA as well as typical reported issues from AAD studies. The study should be separated into 2 parts. Part 1 should compare RFA with AADs for younger patients with paroxysmal AF without structural heart disease. Then, flecainide, propafenone, sotalol, dofetilide, and dronedarone would be reasonable therapy. RFA probably would be very competitive in this part. Part 2 should compare older patients with persistent AF with structural heart disease with a CHADS score of at least 2. In this case, amiodarone and dronedarone would be the only reasonable agents. I would recommend anticoagulation for all patients in part 2. I have doubts as to the competitiveness of RFA in this population, especially if there are more than 50 sites. Each part should include a third group of patients managed with rate control only.
In conclusion, I agree that RFA should be considered as a frontline therapy for maintaining sinus rhythm in some patients with a history of AF. I disagree, however, with the way AADs have been portrayed in the meta-analysis by Calkins et al. The authors should have mentioned some of these issues in the limitations section of their report.
